Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metformin: a biguanide

J J Tanja, T M Langlass

    The Diabetes Educator
    |November 1, 1995
    PubMed
    Summary

    Metformin effectively treats type II diabetes without causing hypoglycemia. This oral medication is safe when monitored for liver and kidney function, and is now FDA-approved as Glucophage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Standard gentamicin dosage regimen in neonates.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
    Same author

    Letter: Monitoring anticoagulant therapy.

    American journal of hospital pharmacy·1976
    Same author

    Letter: IRS ruling on hospital pharmacy residencies.

    American journal of hospital pharmacy·1975
    Same author

    Problems encountered by pharmacy students conducting patient interviews.

    American journal of hospital pharmacy·1972
    Same author

    Precipitates found in admixtures of potassium chloride and dextrose 5 percent in water.

    American journal of hospital pharmacy·1970

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Internal Medicine

    Background:

    • Non-insulin-dependent diabetes mellitus (NIDDM), or type II diabetes, is a prevalent metabolic disorder.
    • Current treatments for NIDDM include oral agents, with varying efficacy and side effect profiles.
    • Sulfonylureas are a class of oral hypoglycemic agents with a risk of inducing hypoglycemia.

    Purpose of the Study:

    • To evaluate the efficacy and safety of metformin as an oral treatment for type II diabetes.
    • To compare the hypoglycemic potential of metformin with that of sulfonylureas.
    • To highlight the importance of monitoring hepatic and renal function during metformin therapy.

    Main Methods:

    • Review of existing clinical data and pharmacological studies on metformin.
    • Analysis of adverse event reports, focusing on hypoglycemia, hepatic, and renal function.
    • Comparison of metformin's efficacy and safety profile against other oral antidiabetic agents.

    Main Results:

    • Metformin demonstrates significant efficacy in managing type II diabetes.
    • Unlike sulfonylureas, metformin does not typically cause hypoglycemia when used appropriately.
    • Metformin requires monitoring of hepatic and renal function for safe administration.

    Conclusions:

    • Metformin is a safe and effective oral agent for type II diabetes management.
    • It offers a lower risk of hypoglycemia compared to sulfonylureas.
    • Adherence to contraindications and patient monitoring are crucial for optimizing metformin therapy.

    Related Experiment Videos